Daily Endocrinology Research Analysis
Three mechanistic and translational studies reshape endocrine-metabolic science: a microbiota-derived peptide (corisin) is identified as a driver of diabetic kidney fibrosis with antibody-based mitigation in mice; branched-chain amino acid catabolic defects trigger PKM2-dependent podocyte reprogramming and apoptosis in diabetic kidney disease; and patient HLA-matched iPSC pituitary organoids demonstrate cytotoxic T-cell–mediated anti-PIT-1 hypophysitis and drug responsiveness.
Summary
Three mechanistic and translational studies reshape endocrine-metabolic science: a microbiota-derived peptide (corisin) is identified as a driver of diabetic kidney fibrosis with antibody-based mitigation in mice; branched-chain amino acid catabolic defects trigger PKM2-dependent podocyte reprogramming and apoptosis in diabetic kidney disease; and patient HLA-matched iPSC pituitary organoids demonstrate cytotoxic T-cell–mediated anti-PIT-1 hypophysitis and drug responsiveness.
Research Themes
- Microbiome-derived effectors and diabetic kidney disease
- Metabolic reprogramming in podocytes via PKM2 under BCAA dysmetabolism
- Patient-specific organoid platforms for endocrine autoimmunity
Selected Articles
1. Microbiota-derived corisin accelerates kidney fibrosis by promoting cellular aging.
This translational study identifies corisin as a microbiota-derived peptide that drives diabetic kidney fibrosis. Elevated corisin correlates with disease severity in humans, and monoclonal anti-corisin therapy reduces nephropathy in diabetic mice, implicating cellular senescence, EMT, and apoptosis as mechanisms.
Impact: Reveals a novel, targetable microbiota-derived driver of diabetic kidney disease with therapeutic proof-of-concept using a monoclonal antibody.
Clinical Implications: Corisin may serve as a biomarker for risk stratification in diabetic kidney disease and as a therapeutic target; anti-corisin biologics warrant early-phase clinical development.
Key Findings
- Serum corisin is markedly elevated in diabetic CKD and correlates with disease stage and renal function decline.
- Anti-corisin monoclonal antibody significantly attenuates nephropathy severity and fibrosis in diabetic mice.
- Corisin binds human serum albumin, potentially enhancing renal accumulation, and induces cellular senescence, EMT, and apoptosis in kidney cells.
Methodological Strengths
- Integrated human case-control serum analysis with mechanistic mouse models and interventional antibody studies.
- Molecular dynamics and experimental validation of corisin–albumin interaction supporting pharmacokinetic plausibility.
Limitations
- Human sample size and cohort characteristics were not detailed, limiting generalizability and confounder assessment.
- Therapeutic efficacy demonstrated only in preclinical models; safety and translational dosing remain unknown.
Future Directions: Validate corisin as a prognostic biomarker in prospective diabetic cohorts; initiate first-in-human studies of anti-corisin therapeutics; delineate upstream microbial sources and host regulation of corisin.
The increasing global prevalence of diabetic nephropathy poses substantial health and economic burdens. Currently, effective anti-fibrotic therapies for managing kidney fibrosis associated with chronic kidney disease are lacking. This study reveals corisin, a microbiota-derived peptide, as a central driver in the progression of diabetic kidney fibrosis. Corisin levels were found to be markedly elevated in the serum of diabetic chronic kidney disease patients relative to healthy controls, with strong correlations to advanced disease stages and declining renal function. In a murine model of kidney fibrosis, corisin levels were similarly heightened, directly contributing to increased inflammation and worsening fibrosis and renal impairment. Notably, the use of a monoclonal anti-corisin antibody significantly reduced nephropathy severity in diabetic mice. Through molecular dynamics simulations and experimental validation, we demonstrated that corisin interacts with human serum albumin, potentially enhancing its renal accumulation and pathological impact. The pathogenic mechanism of corisin involves the acceleration of cellular senescence and the induction of epithelial-mesenchymal transition and apoptosis in kidney cells. These findings underscore the critical role of corisin in progressive diabetic nephropathy and suggest a promising new target for therapeutic intervention.
2. Branched-chain amino acids contribute to diabetic kidney disease progression via PKM2-mediated podocyte metabolic reprogramming and apoptosis.
BCAA catabolic defects in podocytes are identified as a trigger for DKD, acting through PKM2 depolymerization to reprogram metabolism and drive apoptosis. Genetic and nutritional perturbations reproduce DKD phenotypes, nominating BCAA catabolism and PKM2 activation as preventive or therapeutic targets.
Impact: Provides a mechanistic link between amino acid dysmetabolism and podocyte failure in DKD, with actionable targets (BCAA catabolism, PKM2) for intervention.
Clinical Implications: Supports caution with high-BCAA supplementation in diabetes and prioritizes development of PKM2 activators or strategies to restore BCAA catabolism as DKD-modifying therapies.
Key Findings
- Podocytes in human DKD and db/db mice show specific defects in BCAA catabolism.
- Podocyte PP2Cm knockout or exogenous BCAA supplementation induces DKD phenotypes (podocyte dysfunction/apoptosis, glomerular lesions, proteinuria) in HF-fed mice.
- BCAAs promote PKM2 depolymerization, shifting metabolism away from OXPHOS towards serine/folate pathways and, via nuclear PKM2-DDIT3, upregulate Chac1 and Trib3 to trigger apoptosis.
Methodological Strengths
- Multi-system validation across human tissue, genetic mouse models, and dietary interventions.
- Mechanistic dissection linking metabolic flux changes to specific transcriptional apoptosis pathways (DDIT3–Chac1/Trib3).
Limitations
- Clinical translatability (dose-response, safety) of PKM2 activation or BCAA manipulation remains untested in humans.
- Quantitative human sample size and covariate adjustment details are not provided.
Future Directions: Develop PKM2 activators and BCAA-catabolism–restoring strategies; test dietary BCAA modulation in controlled clinical studies; validate podocyte metabolic signatures as DKD biomarkers.
Approximately 30-40% of patients with diabetes develop diabetic kidney disease (DKD). Identifying decisive factors for DKD initiation is crucial. Here, we observed that glomerular podocytes in male and female patients with DKD and db/db mice specifically displayed BCAA catabolic defects. Podocyte-specific PP2Cm (a key BCAA catabolism enzyme) knockout or exogenous BCAA supplementation induced DKD phenotypes including podocyte dysfunction/apoptosis, glomerular pathology, and proteinuria in high-fat (HF)-diet-fed male mice. Mechanistically, BCAAs promoted PKM2 depolymerization and inactivation in podocytes. Depolymerized PKM2 suppressed glucose oxidative phosphorylation (OXPHOS), diverting glucose metabolism towards serine biosynthesis and folate metabolism. Depolymerized PKM2 is also co-transported with DDIT3 into the nucleus, acting as a co-transcriptional factor to enhance DDIT3 transcriptional activity, which promotes Chac1 and Trib3 expression and directly inducing podocyte apoptosis. Thus, BCAA catabolic defects may be one of the missing factors that determine DKD initiation. Targeting BCAA catabolism or PKM2 activation is a promising DKD prevention strategy.
3. Modeling of T cell-mediated autoimmune pituitary disease using human induced pluripotent stem cell-originated organoid.
HLA-matched iPSC pituitary organoids co-cultured with patient-derived PIT-1–reactive CTLs provide direct evidence of T cell–mediated cytotoxicity in anti-PIT-1 hypophysitis, which is suppressible by immunosuppressants. The platform enables dissection of epitope–HLA–T cell interactions in endocrine autoimmunity.
Impact: Establishes a patient-specific, mechanistically faithful organoid platform that proves T cell–mediated pathogenesis and enables personalized testing of immunosuppression in a rare endocrine autoimmune disease.
Clinical Implications: Supports diagnosis and therapeutic decision-making via ex vivo testing of immunosuppressants; provides a blueprint for modeling other T cell–mediated endocrine autoimmune conditions.
Key Findings
- Autologous co-culture of HLA-matched iPSC pituitary organoids with patient PIT-1–reactive CTLs induces specific cytotoxicity against PIT-1–positive cells.
- Cytotoxicity is suppressed by dexamethasone and cyclosporin A, demonstrating pharmacologic modulability.
- Multiple epitope–CTL–HLA combinations contribute to disease pathogenesis, highlighting heterogeneity.
Methodological Strengths
- Patient-specific HLA-matched organoids with autologous CTL co-culture provide high physiological relevance.
- Functional pharmacologic validation demonstrates clinical translatability of the platform.
Limitations
- In vitro organoid system lacks systemic immune and endocrine microenvironment interactions.
- Number of patient specimens and breadth of epitope mapping are limited.
Future Directions: Scale to larger patient cohorts to correlate ex vivo responses with clinical outcomes; expand epitope mapping; adapt the platform to other pituitary and endocrine autoimmune diseases.
Anti-pituitary-specific transcription factor (PIT)-1 hypophysitis is an autoimmune disease characterized by hormone secretion impairment from PIT-1-expressing pituitary cells, accompanied by malignancies with ectopic PIT-1 expression. Cytotoxic T cells (CTL) targeting PIT-1-positive cells have been implicated in disease development, yet direct evidence is lacking. As human leukocyte antigen (HLA)-matching is required for modeling T cell-mediated autoimmune diseases, we employ induced pluripotent stem cells (iPSC) to generate pituitary organoids harboring the patients' HLA haplotype and coculture the organoids with PIT-1-reactive CTLs isolated from the patients' peripheral blood mononuclear cells. The coculture demonstrates specific CTL-mediated cytotoxicity against PIT-1-positive cells exclusively in autologous conditions, with this cytotoxicity inhibited by immunosuppressive agents such as dexamethasone and cyclosporin A. Multiple combinations of epitopes, CTLs, and HLA molecules are responsible for pathogenesis. These data demonstrate CTL-mediated autoimmunity in anti-PIT-1 hypophysitis and highlight the potential application of this strategy for other T cell-mediated autoimmune diseases.